Clinical Trial

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study acronym: SURF302
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2025-05-20; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-06-02
Trial Details
NCT Number NCT06995677
Lead Sponsor Tyra Biosciences, Inc
Conditions Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Enrollment 90 participants
Start Date 2025-06-27
Primary Completion 2028-02 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06